US2004208875A1PendingUtilityA1
Method for treating amyloidosis
Est. expiryMar 15, 2015(expired)· nominal 20-yr term from priority
A61P 43/00C07H 15/04A61K 31/41C07C 305/10A61K 31/255A61K 31/095A61K 31/34A61K 31/185A61K 31/70C07C 309/05A61K 47/58C07H 11/00C07D 491/04A61K 47/51A61K 47/549A61P 3/00A61K 47/55A61K 47/555
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.
Claims
exact text as granted — not AI-modified1 . (cancelled)
2 . A method for treating Alzheimer's disease, comprising administering to a subject an effective amount of 3-amino-1-propanesulfonic acid or a pharmaceutically acceptable salt thereof, such that Alzheimer's disease is treated or prevented.
3 . A method for treating Alzheimer's disease, comprising administering to a subject having Alzheimer's disease an effective amount of 3-amino-1-propanesulfonic acid or a pharmaceutically acceptable salt thereof, such that Alzheimer's disease is treated.
4 . A method for treating Alzheimer's disease, comprising administering to a subject in need thereof an effective amount of 3-amino-1-propanesulfonic acid or a pharmaceutically acceptable salt thereof, such that Alzheimer's disease is treated or prevented.
5 . A method for treating Alzheimer's disease, comprising administering to a subject in need thereof an effective amount of an agent such that Alzheimer's disease is treated or prevented in said subject by 3-amino-1-propanesulfonic acid or a salt thereof.
6 . A method for treating Alzheimer's disease, comprising administering to a subject an effective amount of an agent such that Alzheimer's disease is treated or prevented in said subject by 3-amino-1-propanesulfonic acid or a salt thereof.
7 . The method of claim 2 , wherein Alzheimer's disease is prevented in said subject.
8 . The method of claim 4 , wherein Alzheimer's disease is prevented in said subject.
9 . The method of claim 5 , wherein Alzheimer's disease is prevented in said subject.
10 . The method of claim 6 , wherein Alzheimer's disease is prevented in said subject.
11 . The method of any one of claims 2 - 4 , 7 and 8 , wherein 3-amino-1-propanesulfonic acid is administered to said subject.
12 . The method of any one of claims 5 , 6 , 9 and 10 , wherein said subject is treated by 3-amino-1-propanesulfonic acid.
13 . The method of any one of claims 2 - 4 , 7 and 8 , wherein a pharmaceutically acceptable salt of 3-amino-1-propanesulfonic acid is administered to said subject.
14 . The method of any one of claims 5 , 6 , 9 and 10 , wherein said subject is treated by a salt of 3-amino-1-propanesulfonic acid.
15 . The method of claim 13 , wherein said pharmaceutically acceptable salt is a sodium salt of 3-amino-1-propanesulfonic acid.
16 . The method of claim 14 , wherein said salt is a sodium salt of 3-amino-1-propanesulfonic acid.
17 . The method of any one of claims 2 - 4 , 7 and 8 , wherein said 3-amino-1-propane-sulfonic acid or pharmaceutically acceptable salt thereof is administered to said subject in a pharmaceutical composition further comprising a pharmaceutically acceptable vehicle.
18 . The method of any one of claims 5 , 6 , 9 and 10 , wherein said agent is administered to said subject in a pharmaceutical composition further comprising a pharmaceutically acceptable vehicle.
19 . The method of claim 11 , wherein 3-amino-1-propanesulfonic acid is administered to said subject in a pharmaceutical composition further comprising a pharmaceutically acceptable vehicle.
20 . The method of claim 12 , wherein the agent is administered to said subject in a pharmaceutical composition further comprising a pharmaceutically acceptable vehicle.
21 . The method of claim 13 , wherein said pharmaceutically acceptable salt of 3-amino-1-propanesulfonic acid is administered to said subject in a pharmaceutical composition further comprising a pharmaceutically acceptable vehicle.
22 . The method of claim 14 , wherein the agent is administered to said subject in a pharmaceutical composition further comprising a pharmaceutically acceptable vehicle.
23 . The method of claim 15 , wherein said sodium salt of 3-amino-1-propanesulfonic acid is administered to the subject in a pharmaceutical composition further comprising a pharmaceutically acceptable vehicle.
24 . The method of claim 16 , wherein the agent is administered to said subject in a pharmaceutical composition further comprising a pharmaceutically acceptable vehicle.
25 . The method of any one of claims 2 - 6 , wherein said administering step is oral administration.
26 . The method of claim 7 , wherein said administering step is oral administration.
27 . The method of claim 8 , wherein said administering step is oral administration.
28 . The method of claim 9 , wherein said administering step is oral administration.
29 . The method of claim 10 , wherein said administering step is oral administration.
30 . The method of claim 11 , wherein said administering step is oral administration.
31 . The method of claim 12 , wherein said administering step is oral administration.
32 . The method of claim 13 , wherein said administering step is oral administration.
33 . The method of claim 14 , wherein said administering step is oral administration.
34 . The method of claim 15 , wherein said administering step is oral administration.
35 . The method of claim 16 , wherein said administering step is oral administration.
36 . The method of claim 17 , wherein said administering step is oral administration.
37 . The method of claim 18 , wherein said administering step is oral administration.
38 . The method of claim 19 , wherein said administering step is oral administration.
39 . The method of claim 20 , wherein said administering step is oral administration.
40 . The method of claim 21 , wherein said administering step is oral administration.
41 . The method of claim 22 , wherein said administering step is oral administration.
42 . The method of claim 23 , wherein said administering step is oral administration.
43 . The method of claim 24 , wherein said administering step is oral administration.
44 . The method of any one of claims 2 - 6 , wherein said subject is human.
45 . The method of claim 7 , wherein said subject is human.
46 . The method of claim 8 , wherein the subject is human.
47 . The method of claim 9 , wherein said subject is human.
48 . The method of claim 10 , wherein said subject is human.
49 . The method of claim 11 , wherein said subject is human.
50 . The method of claim 12 , wherein said subject is human.
51 . The method of claim 13 , wherein said subject is human.
52 . The method of claim 14 , wherein said subject is human.
53 . The method of claim 15 , wherein said subject is human.
54 . The method of claim 16 , wherein said subject is human.
55 . The method of claim 17 , wherein said subject is human.
56 . The method of claim 18 , wherein said subject is human.
57 . The method of claim 19 , wherein said subject is human.
58 . The method of claim 20 , wherein said subject is human.
59 . The method of claim 21 , wherein said subject is human.
60 . The method of claim 22 , wherein said subject is human.
61 . The method of claim 23 , wherein said subject is human.
62 . The method of claim 24 , wherein said subject is human.
63 . The method of claim 25 , wherein said subject is human.
64 . The method of claim 26 , wherein said subject is human.
65 . The method of claim 27 , wherein said subject is human.
66 . The method of claim 28 , wherein said subject is human.
67 . The method of claim 29 , wherein said subject is human.
68 . The method of claim 30 , wherein said subject is human.
69 . The method of claim 31 , wherein said subject is human.
70 . The method of claim 32 , wherein said subject is human.
71 . The method of claim 33 , wherein said subject is human.
72 . The method of claim 34 , wherein said subject is human.
73 . The method of claim 35 , wherein said subject is human.
74 . The method of claim 36 , wherein said subject is human.
75 . The method of claim 37 , wherein said subject is human.
76 . The method of claim 38 , wherein said subject is human.
77 . The method of claim 39 , wherein said subject is human.
78 . The method of claim 40 , wherein said subject is human.
79 . The method of claim 41 , wherein said subject is human.
80 . The method of claim 42 , wherein said subject is human.
81 . The method of claim 43 , wherein said subject is human.Join the waitlist — get patent alerts
Track US2004208875A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.